AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05929066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04547439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin 3 mg will be taken nightly for 8 weeks
Study NCT05019352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb cytokine adsorber
Description: device for extracorporeal hemoadsorption
Study NCT05019352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT
Description: continuous renal replacement therapy
Study NCT05428449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT20029 Gel
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Study NCT05428449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GT20029 Gel Placebo
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Study NCT04547439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be given nightly for 8 weeks
Study NCT05581173 — intervention group
Intervention type: DEVICE
Intervention: Purastat SAP gel application
Description: Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
Study NCT05893498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFRangio
Description: A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
Study NCT05893498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR or NHPR
Description: Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
Study NCT05851625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Description: Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
Study NCT05851625 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plesterin
Description: The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
Study NCT05509738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses.
Study NCT04835532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone gereration
Description: guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation.
Study NCT05173662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process
Description: Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
Study NCT05270343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vit D3) 400Unit Cap
Description: Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
Study NCT06505512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT06411197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: Injection with hypertonic saline (7%)
Study NCT06411197 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline injection
Description: Injection with isotonic saline (0.9%)
Study NCT04923191 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
Description: percutaneous coronary intervention
Study NCT05089942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Insulin Patch ZJSRM2021
Description: health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
Study NCT05089942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: health subjects receive placebo patch
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
Study NCT06291545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）
Description: One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
Study NCT05286814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intera 3000 Hepatic Artery Infusion Pump (HAIP)
Description: Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
Study NCT06291545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ScoreFlex NC Coronary Dilatation Catheter
Description: One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
Study NCT06068647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations
Description: Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level.
Study NCT05231538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy
Description: NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS01ADC
Description: PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
Study NCT05286814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
Study NCT05821855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XEN45 Glaucoma Treatment System
Description: Ab interno implantation
Study NCT05821855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Surgical Intervention
Study NCT04773353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta (FE 999049)
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.
Study NCT04773353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa (GONAL-F)
Description: GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
Study NCT05708833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous venous access
Description: Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
Study NCT05708833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral venous access
Description: Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
Study NCT04954833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-200
Description: TEST Lens
Study NCT05231538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: stretching, passive range of motion, and active range of motion).
Study NCT04677049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin CRT
Description: A controlled release technology (CRT) tablet of Niacin
Study NCT06237829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single bump acuity
Description: Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (\<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, \~100% success rate control, will be constructed
Study NCT06237829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal spacing between bumps
Description: Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
Study NCT06237829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving signal from a single bump with designer materials
Description: Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps).
Study NCT05984628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
Study NCT05984628 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: blank solvent
Description: After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
Study NCT04954833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-118
Description: CONTROL Lens
Study NCT06204289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Supportive Care Programme
Description: Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
Study NCT04829110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETOH
Description: Participants will consume Vodka
Study NCT05825092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgel Topical Product
Description: AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
Study NCT05825092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physical performance
Description: Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Physical performance
Description: Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strength
Description: Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Muscle strength
Description: Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Muscular mass
Description: Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Muscular mass
Description: Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Test: Functional status
Description: Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Test: Functional status
Description: Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen muscular consumption
Description: Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate
Study NCT05825092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen muscular consumption
Description: Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate